NR-SAFE: A Randomized, Double-Blind Safety Trial of High Dose Nicotinamide Riboside in Parkinson’s

Objective

To assess the safety of high-dose NR through the absence of clinically significant adverse events, and assess short-term tolerability and impacts on NAD+, as well as clinical severity of Parkinson’s disease (PD).

Study Design

Randomized, double-blind, placebo-controlled, phase I study in 20 idiopathic PD patients

Dose

3000 mg

Duration

4 weeks

Key Outcomes

  • High-dose NR supplementation was safe and well-tolerated with no related adverse events.

  • NR did not alter whole blood homocysteine, or other major methyl donor groups, suggesting no impact on methyl donor group pool.

  • NR significantly improved clinical symptoms of PD, suggesting augmenting NAD+ levels may have a symptomatic anti-Parkinson effect.

Clinical, Neurological HealthANAD StaffParkinson's Disease